Explore

Trendline Trendline
Incyte and Genesis Expand AI Drug Collaboration to Over $1 Billion

Incyte and Genesis Expand AI Drug Collaboration to Over $1 Billion

Incyte and Genesis Expand AI Drug Collaboration to Over $1 Billion
Trendline Trendline
Eli Lilly Partners with Ascidian Therapeutics for $1.9 Billion RNA Exon Editing Deal Targeting Kidney Diseases

Eli Lilly Partners with Ascidian Therapeutics for $1.9 Billion RNA Exon Editing Deal Targeting Kidney Diseases

Eli Lilly Partners with Ascidian Therapeutics for $1.9 Billion RNA Exon Editing Deal Targeting Kidney Diseases
Reuters Reuters
Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns

Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns

June 2 (Reuters) - Shares of Fulcrum Therapeutics plunged 50% in premarket trading on Tuesday after the company said it would abandon development of its experimental sickle-cell disease drug following cancer-risk concerns raised by the U.S.
Trendline Trendline
Arrowhead Pharmaceuticals to Participate in Major Healthcare Conferences in June 2026

Arrowhead Pharmaceuticals to Participate in Major Healthcare Conferences in June 2026

Arrowhead Pharmaceuticals to Participate in Major Healthcare Conferences in June 2026
Trendline Trendline
Eli Lilly Partners with Ascidian for $1.9 Billion Kidney Disease RNA-Editing Collaboration

Eli Lilly Partners with Ascidian for $1.9 Billion Kidney Disease RNA-Editing Collaboration

Eli Lilly Partners with Ascidian for $1.9 Billion Kidney Disease RNA-Editing Collaboration
Trendline Trendline
Celcuity Faces Investor Backlash After Disappointing Trial Results for Breast Cancer Drug

Celcuity Faces Investor Backlash After Disappointing Trial Results for Breast Cancer Drug

Celcuity Faces Investor Backlash After Disappointing Trial Results for Breast Cancer Drug
Trendline Trendline
Eli Lilly Secures Licensing for Hanmi's GLP-2 Drug in $1.26 Billion Deal

Eli Lilly Secures Licensing for Hanmi's GLP-2 Drug in $1.26 Billion Deal

Eli Lilly Secures Licensing for Hanmi's GLP-2 Drug in $1.26 Billion Deal
Trendline Trendline
Servier Invests $2.65 Billion in Edgewise's Muscular Dystrophy Drug Development

Servier Invests $2.65 Billion in Edgewise's Muscular Dystrophy Drug Development

Servier Invests $2.65 Billion in Edgewise's Muscular Dystrophy Drug Development
Trendline Trendline
Biohaven Targets Obesity Market to Recover from Clinical Setbacks

Biohaven Targets Obesity Market to Recover from Clinical Setbacks

Biohaven Targets Obesity Market to Recover from Clinical Setbacks
Trendline Trendline
Servier Acquires Edgewise's Muscular Dystrophy Business for $2.65 Billion

Servier Acquires Edgewise's Muscular Dystrophy Business for $2.65 Billion

Servier Acquires Edgewise's Muscular Dystrophy Business for $2.65 Billion
Trendline Trendline
Hanmi and Lilly Enter Licensing Agreement for Sonefpeglutide Development

Hanmi and Lilly Enter Licensing Agreement for Sonefpeglutide Development

Hanmi and Lilly Enter Licensing Agreement for Sonefpeglutide Development
Trendline Trendline
Seaport Therapeutics to Engage in Key Investor Conferences Amidst Neuropsychiatric Drug Development

Seaport Therapeutics to Engage in Key Investor Conferences Amidst Neuropsychiatric Drug Development

Seaport Therapeutics to Engage in Key Investor Conferences Amidst Neuropsychiatric Drug Development